<DOC>
	<DOCNO>NCT01307241</DOCNO>
	<brief_summary>Results actual treatment ALL optimal . New prognostic factor , may determine clinical &amp; molecular response require . Hyper-CVAD internationally accept schema patient . The objective pilot study evaluate polymorphism regard RFC ( reduce folate carrier ) MTHFR enzyme , may affect function protein , therefore intracellular bioavailability methotrexate . Also , expression level hENT1 dCK evaluate , since gene codify citarabine intracellular transport activation , respectively . Clinical characteristic tabulate analyzed responder &amp; non-responders patient . Uni- &amp; multivariate analysis do evaluate factor influence response survival .</brief_summary>
	<brief_title>RFC MTHFR SNPs &amp; hENT1- dCK Expression Prognostic Factors ALL &amp; hENT1- dCK Expression Prognostic Factors AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Age : old 15 year . Male , female . Normal renal &amp; liver function . Without previous treatment . Candidate treat hyperCVAD Schema ( ALL patient ) . Candidate receive induction remission cytarabine ( AML patient ) Patients candidate receive methotrexate cytarabine .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>prognostic factor</keyword>
	<keyword>pharmacogenetics .</keyword>
</DOC>